<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drugs Wholesale</title>
	<atom:link href="http://www.stockbloghub.com/category/drugs-wholesale/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABC) AmerisourceBergen Posts Modest Second Quarter Results</title>
		<link>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760</link>
		<comments>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99760</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) posted second quarter fiscal 2012 earnings of 81 cents per share, in line with the Zacks Consensus Estimate. However, earnings increased 5.2% from the year-ago period, spurred by higher revenues and a lower share count. Revenues Total revenue for the second quarter edged up 1.6% to $20.1 billion, which were also in line with the Zacks Consensus Estimate. The modest advance in revenues was the result of a 6% increase in AmerisourceBergen Specialty Group’s revenue. The revenue increase for the AmerisourceBergen Specialty Group segment was driven by growth in third party logistics and vaccine and physician office distribution business. The robust performance of AmerisourceBergen Drug Corporation’s institutional segment was offset by the loss of a significant retail customer. TheraCom, a recent acquisition, also contributed toward the quarter’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134</link>
		<comments>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88134</guid>
		<description><![CDATA[We reiterate our Outperform rating on Cardinal Health (CAH). Its first-quarter fiscal 2012 (ended September 30) adjusted earnings per share of 73 cents beat the Zacks Consensus Estimate of 72 cents. Earnings from continuing operations (as reported) dropped about 19% year over year reflecting a previous-year gain from the sale of CareFusion (CFN) shares. Sales for the first quarter rose 10% year over year to $26.8 billion, exceeding the Zacks Consensus Estimate of $26.3 billion. Sales were boosted by growth across the board, notably, buoyancy in the larger Pharmaceutical segment. Revenues from the Pharmaceutical segment spiked 10% year over year in the quarter. Acquisitions contributed to growth as did organic growth from pre-existing clients. Sales from the smaller Medical segment climbed 10%, driven by higher sales to existing and net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764</link>
		<comments>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764#comments</comments>
		<pubDate>Fri, 07 Oct 2011 16:27:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84764</guid>
		<description><![CDATA[We recently upgraded our rating on Cardinal Health, Inc. (CAH) to Outperform. Earnings for the fourth quarter narrowly beat the Zacks Consensus Estimate. Cardinal&#8217;s size and diversity partly insulate it from economic cycles, and its generics business continues to grow at a healthy pace. Moreover, Cardinal&#8217;s Pharmaceutical and Medical segments have revamped operations. The company continues to nurture its specialty platforms and engage in periodic tuck-in acquisitions. Although client and supplier concentration and reliance on group purchasing organizations remain areas of concern, the same is partly mitigated through long-term contracts. While margins are thin in the bulk Pharma business, the business mix is evolving in favor of the non-bulk segment. Robust cash flow, high cash balance and revolving credit facility bestow liquidity for share repurchase and acquisitions. CARDINAL HEALTH (CAH): ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282</link>
		<comments>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282#comments</comments>
		<pubDate>Mon, 03 Oct 2011 19:20:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84282</guid>
		<description><![CDATA[We upgrade our rating on Cardinal Health, Inc. (CAH) to Outperform. Earnings for the fourth quarter narrowly beat the Zacks Consensus Estimate. Cardinal&#8217;s size and diversity partly insulate it from economic cycles. Its generics business continues to grow at a healthy pace. Moreover, Cardinal&#8217;s Pharmaceutical and Medical segments have revamped operations. The company continues to nurture its specialty platforms and engage in periodic tuck-in acquisitions. Although client and supplier concentration and reliance on group purchasing organizations remain areas of concern, the same is partly mitigated through long-term contracts. While margins are thin in the bulk Pharma business, the business mix is evolving in favor of the non-bulk segment. Robust cash flow, high cash balance and revolving credit facility bestow liquidity for share repurchase and acquisitions. CARDINAL HEALTH (CAH): Free Stock ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113</link>
		<comments>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:29:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82113</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue to benefit from growth in the pharmaceutical industry, which is driven by several factors like aging population, increased use of generics, introduction of new treatments, increased use of drug therapies and favorable legislative developments. The aforesaid points are continually helping the company, which increased its 2011 earnings guidance range following the release of the third quarter fiscal 2011 financial results. AmerisourceBergen now expects 2011 earnings to lie in the range of $2.52 &#8211; $2.56 per share (previous guidance: $2.41 &#8211; $2.49). We expect fiscal 2011 earnings to increase almost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670</link>
		<comments>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:59:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77670</guid>
		<description><![CDATA[McKesson Corp.&#8217;s (MCK) fourth quarter fiscal 2011 earnings of $1.66 per share outpaced the Zacks Consensus Estimate and the year-ago earnings. Revenues climbed 8% to $28.9 billion. McKesson&#8217;s fiscal 2012 guidance was also above expectations. The company expects fiscal 2012 earnings in the range of $5.99 and $6.19 per share. Following the earnings announcement, we raised our 2012 earnings estimate by 50 cents to $6.10. Based on the company&#8217;s performance and guidance, we are upgrading McKesson to Outperform. We believe that the company will continue performing well. Factors like an aging population, increased use of generics and growing demand for specialty pharmaceutical products should help drive growth in the Distribution Solutions segment. We currently have a target price of $100.00 on McKesson. MCKESSON CORP (MCK): Free Stock Analysis Report Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/mck-mckesson-corporation-bull-of-the-day-2/77670/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779</link>
		<comments>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779#comments</comments>
		<pubDate>Mon, 20 Jun 2011 15:24:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76779</guid>
		<description><![CDATA[McKesson (MCK) reported strong fourth quarter 2011 results with EPS of $1.66, outpacing the Zacks Consensus Estimate and the year-ago earnings. Revenues climbed 8% to $28.9 billion. McKesson&#8217;s fiscal 2012 guidance was also above expectations. The company expects fiscal 2012 earnings in the range of $5.99 and $6.19 per share. Based on the company s performance and the encouraging outlook for fiscal 2012, we are upgrading McKesson to Outperform from Neutral. McKesson is a major player in the pharmaceutical and medical supplies distribution market, and we believe that several factors like an aging population, increased use of generics, and growing demand for specialty pharmaceutical products, especially oncology drugs, should help drive growth in the Distribution Solutions segment. McKesson&#8217;s current trailing 12-month earnings multiple is 15.7, compared with the industry average ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/mck-mckesson-corporation-bull-of-the-day/76779/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Shines &#8211; Provides 2012 View</title>
		<link>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263</link>
		<comments>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263#comments</comments>
		<pubDate>Wed, 04 May 2011 17:36:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73263</guid>
		<description><![CDATA[McKesson Corp.’s (MCK) fourth quarter fiscal 2011 earnings of $1.66 per share (excluding special items) beat the Zacks Consensus Estimate by 6 cents and the year-ago earnings by 40 cents. For fiscal 2011, earnings (excluding special items) came in at $5.00 per share, surpassing the Zacks Consensus Estimate of $4.92 and the previous-year earnings of $4.58 per share. Including expenses associated with the acquisition of US Oncology, earnings for the quarter and the year came in at $1.62 and $4.86 per share, respectively. Higher revenues and lower share count helped boost earnings. Revenues for the fourth quarter climbed 8% to $28.9 billion, marginally beating the Zacks Consensus Estimate of $28.5 billion. Full-year 2011 revenues of $112.1 billion was also ahead of the Zacks Consensus Estimate of $111.7 billion and the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/mck-mckesson-shines-provides-2012-view/73263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Third Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565</link>
		<comments>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72565</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report its third-quarter fiscal 2011 (ending March) results on Thursday, April 28. The company expects earnings per share in the range of $2.54 to $2.60 for fiscal 2011. The current Zacks Consensus Estimate for revenues and earnings for the third quarter are $25.6 billion and 69 cents per share, respectively. Second Quarter Recap Cardinal Health reported second-quarter fiscal 2011 adjusted earnings per share of 69 cents, beating the Zacks Consensus Estimate of 61 cents and surpassing the year-ago results of 57 cents. Total sales were up 2% year over year to $25.4 billion, beating the Zacks Consensus Estimate. Higher sales from the core Pharmaceutical division were partly offset by a modest decline in the Medical segment. Revenues from the larger Pharmaceutical segment moved up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; February 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209</link>
		<comments>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209#comments</comments>
		<pubDate>Fri, 18 Feb 2011 16:44:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67209</guid>
		<description><![CDATA[The publishing industry had long been grappling with sinking advertising revenue, which was exacerbated by the global economic meltdown. This reflected a longer-term secular decline as more readers get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to the Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. However, the recent data available from the Audit Bureau of Circulations (ABC) indicates that the rate of decline in circulation is easing. Newspaper circulation tumbled 5% for the six months ended September 30, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Gets Antitrust Clearance</title>
		<link>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814</link>
		<comments>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814#comments</comments>
		<pubDate>Mon, 20 Dec 2010 20:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62814</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced that antitrust regulators had cleared its $1.3 billion takeover of Kinray, a leading pharma distributor with a presence in the New York metropolitan area. In this regard, the Federal Trade Commission (“FTC”) had approved early termination of waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, for the planned takeover. The cash deal to acquire Kinray will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to shortly close the deal. The company earlier anticipated that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Announces Buy of Kinray</title>
		<link>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379</link>
		<comments>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:25:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60379</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced plans to purchase Kinray Inc., a leading pharma distributor with a presence in the New York metropolitan area. The cash deal will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to close the deal by the end of the current calendar year, or early-2011, depending on regulatory approval and closing conditions. The company anticipates that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal 2012, after taking into account the effect of amortization of intangibles. Kinray is one of the largest privately held distributors of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; November 2010</title>
		<link>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044</link>
		<comments>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:38:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59044</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. The slide in newspaper circulation, which ran through the 1990s and through the 2000s, is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Company News for November 2, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520</link>
		<comments>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520#comments</comments>
		<pubDate>Wed, 03 Nov 2010 06:26:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ADM]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Archer-Daniels-Midland Company]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[Emerson Electric Company]]></category>
		<category><![CDATA[EMR]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[United Parcel Service]]></category>
		<category><![CDATA[UPS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57520</guid>
		<description><![CDATA[• Pfizer&#8217;s (NYSE:PFE) reported third quarter earnings of $0.54, $0.03 above Zacks estimates as revenues surged 39.2% to $16.2 billion, slightly below Zacks estimates of $16.62 billion • Archer Daniels Midland (NYSE:ADM) posted fiscal first quarter earnings of $0.54, off Zacks estimates of $0.75, on inline revenues of $16.8 billion, up 13% YoY, and beating estimates of $15.52 billion • BP (NYSE:BP) posted better-than-expected results and noted plans to consider reinstating its dividend in 2011. Likely costs for the Macondo oil spill were raised to $40 billion • AmerisourceBergen (NYSE:ABC) topped Zacks estimates by $0.02 with fourth quarter interims of $0.50, on a 5.3% revenue gain to $19.7 billion, above Zacks estimates of $19.4 billion • Medco Health (NYSE:MHS) reported estimate-topping third quarter earnings of $0.91, up from estimates of $0.88, on revenues of $16.32 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Prepares for Coming Flu Season</title>
		<link>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709</link>
		<comments>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:13:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53709</guid>
		<description><![CDATA[Cardinal Health (CAH) is taking necessary steps to maintain the supply of influenza vaccines during the forthcoming 2010-2011 flu season. For the first time, the Advisory Committee on Immunization Practices (ACIP) has been asking everyone over 6 months of age to get a flu vaccine. The company is of the opinion that the supplies are sufficient to meet the demand as a result of which everybody will have access to the vaccine. There is no need of prioritization. The flu season of last year resulted in more than 270,000 hospitalizations and 12,000 deaths. However, the upcoming season should not be very severe due to the immunity developed from the last infection and availability of the flu vaccine. Moreover, the flu vaccine will target the H1N1 strain in addition to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sells Remaining CareFusion Shares</title>
		<link>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054</link>
		<comments>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054#comments</comments>
		<pubDate>Sun, 19 Sep 2010 17:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52054</guid>
		<description><![CDATA[Cardinal Health (CAH), a leading distributor of pharmaceuticals and medical supplies, recently sold off the remaining 30.5 million shares of CareFusion Corporation (CFN) for $705.9 million. CareFusion, a San Diego-based vendor for medical equipment and infection control supplies, was spun off from Cardinal Health in 2009. As per the spin-off arrangement, Cardinal Health distributed 0.5 shares of CareFusion common stock for each share of its stock that was outstanding. It retained about 19% of the shares in CareFusion at the time of the distribution. Under the terms of the agreement Cardinal Health was required to dispose of its equity holdings in CareFusion within five years of the distribution (by August 31, 2014). The agreement authorized Cardinal to dispose of its shares through open-market sales, private sales or a combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48444</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250</link>
		<comments>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48250</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655#comments</comments>
		<pubDate>Thu, 12 Aug 2010 05:16:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47655</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, recently reported earnings for fourth-quarter of fiscal year 2010, which beat the Zacks Consensus Estimate by a penny. Revenues grew by a mere 0.5% year over year to $22.3 billion. Pharmaceutical revenues were essentially flat year over year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. The spin-off of CareFusion (CFN) has enabled Cardinal to increase focus on its core healthcare supply chain business. Moreover, Cardinal recently acquired privately held specialty pharmaceutical services company Healthcare Solutions Holding for $667 million. The acquisition has expanded its foothold in the fast-growing specialty pharmaceutical services segment. Agreement – ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Reaffirms Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468</link>
		<comments>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47468</guid>
		<description><![CDATA[We maintain our Neutral recommendation for Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies. Earnings for fourth-quarter fiscal 2010 beat the Zacks Consensus Estimate by a penny. However, profit dipped year-over-year, impacted by the spin-off of the company’s non-core Clinical and Medical Products segment (CareFusion), lower customer pricing and supply disruption in the pharmaceutical segment. Revenues grew by a mere 0.5% year-over-year to $22.3 billion, narrowly missing the Zacks Consensus Estimate. Pharmaceutical revenues were essentially flat year-over-year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. Cardinal is one of the largest global healthcare companies that help pharmacies, hospitals and ambulatory care sites to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health&#8217;s Report Beats Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854</link>
		<comments>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:56:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46854</guid>
		<description><![CDATA[Cardinal Health (CAH) reported fourth-quarter and fiscal 2010 adjusted (excluding one-time expenses) earnings per share of 50 cents and $2.22 respectively, exceeding the Zacks Consensus Estimates of 49 cents and $2.21, respectively, but below the year-ago results of 63 cents and $2.26, respectively. Revenues Total revenue was $24.5 billion in the fourth quarter, up by a mere 0.5% year over year, and $98.5 billion in fiscal 2010, up 3%. Reported results were marginally below the Zacks Consensus Estimates of $24.6 billion and $98.7 billion for the fourth quarter and fiscal year, respectively. Segment-wise Revenue The Pharmaceutical segment reported fourth-quarter revenue of $22.3 billion, up a nominal 0.2%. Sales to non-bulk customers were $11.5 billion, up 3% year over year, while sales to bulk customers were $10.8 billion, down 3%. Generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health &#8211; Increased Dividend by 11%</title>
		<link>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918</link>
		<comments>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:49:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46918</guid>
		<description><![CDATA[Cardinal Health (CAH) is in a stable industry with steady revenues and a safe dividend. Growth and Income The company is expected to grow its EPS 10.8% over the next three to five years. The stock also offers investors a dividend yield of 2.3%. This Zacks #2 Rank stock trades at 13.4x fiscal year 2011 consensus EPS estimates. Business Cardinal Health provides health care products and services primarily in the US. Its largest segment distributes branded and private-label pharmaceuticals to retail customers, hospitals, and alternate care providers. Fiscal Fourth-Quarter Results On August 5, Cardinal reported financial results for the fourth quarter of fiscal year 2010. Cardinal&#8217;s revenue rose 0.5% to $24.5 billion from $24.3 billion in the year-ago quarter. The company earned $0.50 per share, beating the Zacks Consensus Estimate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047</link>
		<comments>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047#comments</comments>
		<pubDate>Tue, 03 Aug 2010 04:23:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46047</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report fourth-quarter and fiscal 2010 (ending June 30, 2010) results on Thursday, August 5, 2010. The company earlier issued earnings per share guidance in the range of $2.15 to $2.20 for fiscal 2010. The current Zacks Consensus Estimate for the fourth quarter is 49 cents, representing an estimated 43.2% year over year decline. Third Quarter Recap Cardinal Health reported third-quarter fiscal 2010 adjusted (excluding one-time gain on sale of CareFusion stock) earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. Total sales increased 1% year over year to $24.3 billion. The company experienced moderate growth in both its business segments, Pharmaceutical (comprising bulk and non bulk customers) and Medical. Revenues for the much larger Pharmaceutical segment increased 0.5% year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Review and Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643</link>
		<comments>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643#comments</comments>
		<pubDate>Tue, 06 Jul 2010 20:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42643</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. The slide in newspaper circulation, which ran through the 1990s and through the 2000s, is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Quarterly Earnings Outperform</title>
		<link>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762</link>
		<comments>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762#comments</comments>
		<pubDate>Fri, 30 Apr 2010 15:52:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35762</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported third quarter fiscal 2010 earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. However, earnings were lower than the year-ago figure of 66 cents. Sales Total sales in the third quarter increased 1% year over year to $24.3 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 0.5% year over year to $22.2 billion. Growth was fueled by higher sales to bulk and non-bulk customers. Sales to bulk customers increased 0.5% year over year to $10.9 billion. Sales to non-bulk customers increased 0.5% year over year to $11.3 billion. Medical segment revenues increased 7% year over year to $2.1 billion. Growth can be primarily attributed to higher sales to existing domestic customers and strong performance of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Beats Forecasts &#8211; Raises Outlook Again</title>
		<link>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742</link>
		<comments>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:32:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34742</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted second quarter fiscal 2010 earnings of 63 cents per share, beating the Zacks Consensus Estimate by 8 cents. Earnings increased 34% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 13% growth in AmerisourceBergen Drug Corp. revenues and a 5% rise in Specialty Group revenues. AmerisourceBergen Drug Corp. revenues were driven by new customer additions and overall market growth. New business accounted for more than 4% of revenue growth. Meanwhile, generic revenues remained strong during the quarter. Gross profit for the second quarter was $612.1 million, which reflected an 11% increase over the year-ago period. The improvement was driven by increased revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; April 2010 &#8211; Stock Review</title>
		<link>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518</link>
		<comments>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518#comments</comments>
		<pubDate>Thu, 01 Apr 2010 14:55:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32518</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade long erosion in newspaper circulation has reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry, but the picture remains gloomy. The slide in newspaper circulation, which ran through the 1990s and into 2000, is accelerating. Earlier, the circulation of newspaper was falling by less than 1%, but the rate of decline accelerated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health &#8211; Earnings Estimates Are Moving Higher</title>
		<link>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442</link>
		<comments>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:51:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29442</guid>
		<description><![CDATA[Cardinal Health (CAH) provides investors with 10% earnings growth and a dividend yield of 2%. Company Description Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies. The company is also a leading provider of products and services that improve the safety and productivity of health-care providers. Cardinal Health manufactures medication infusion and dispensing products, respiratory equipment, and surgical instruments. Stable Business with Growth Potential The company&#8217;s diversified product portfolio generates a steady revenue stream even during economic downturns. Cardinal&#8217;s generic business should remain its fastest growing segment. The company has been expanding relationships with generic manufacturers. These relationships have several benefits including higher levels of service, greater clarity on costs, and more consistent product supply with fewer disruptions. Cardinal management expects its generic business to gain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Upgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680#comments</comments>
		<pubDate>Wed, 10 Feb 2010 21:17:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27680</guid>
		<description><![CDATA[We have recently upgraded Cardinal Health Inc. (CAH) to “Outperform&#8221; with a target price of $37 based on approximately 15.7x our fiscal 2011 EPS estimate of $2.36. Cardinal Health reported second quarter fiscal 2010 earnings per share of 57 cents, beating the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Total sales increased 3% year over year to $24.9 billion, fueled by growth across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11.0 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corporation Reports Robust Quarterly Results</title>
		<link>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140</link>
		<comments>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:26:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27140</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) recently declared a dividend of 8 cents per share. The company pays an industry-leading dividend yield of 1.13%. In late January, the company reported record earnings of 52 cents for the fiscal first quarter, topping the Zacks Consensus Estimate by 13%. Revenue hit a record $19.3 billion, a year-over-year spike of 11.5%. Company Description AmerisourceBergen Corporation, a pharmaceutical services companies serving the United States, Canada and selected global markets, serves both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel. The company distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers. With more than $70 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. Solid Income The company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Beats Expectations and Boosts Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312</link>
		<comments>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:26:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26312</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported second quarter fiscal 2010 earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Sales Total sales in the reported quarter increased 3% year over year to $24.9 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. Margins Gross and operating margins remained unchanged at 3.8% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation Reports Earnings in Line With Analysts</title>
		<link>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150</link>
		<comments>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:45:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26150</guid>
		<description><![CDATA[McKesson Corp. (MCK) reported fiscal third-quarter earnings of $1.19 per share, in line with the Zacks Consensus Estimate. However, earnings increased 13% from the year-ago profit of $1.05. Meanwhile, revenues increased 4% to $28.3 billion, driven by the strong performance of the Distribution Solutions business. The Distribution Solutions segment grew 4% with the U.S. pharmaceutical distribution business, recording a 2% increase in revenues. The loss of two customer buying groups in the U.S. continued to impact the performance of this segment. We believe the performance of the segment will continue to be impacted by lost business through the remainder of the year. Canadian revenues grew 8%, reflecting market growth. Medical-Surgical distribution revenues also increased (up 11%), benefiting from small acquisitions made by the company in late fiscal 2009 and an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corporation Surpasses Expectations &#8211; Ups Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050</link>
		<comments>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050#comments</comments>
		<pubDate>Tue, 26 Jan 2010 22:56:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26050</guid>
		<description><![CDATA[This morning, AmerisourceBergen Corp. (ABC) posted first quarter fiscal 2010 earnings of 52 cents per share, beating the Zacks Consensus Estimate by 6 cents. Earnings increased 44% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 12.9% growth in AmerisourceBergen Drug Corp. revenues and a 7.7% rise in Specialty Group revenues. Generic revenues remained strong during the quarter. Gross profit for the first quarter was $563.4 million, which reflected a 15% increase over the gross profit in the year-ago period. The improvement was driven by increased revenue and new generic pharmaceutical launches, especially in the specialty group. Revenue growth Incorporatedreased gross profit, and expense management helped ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corp Ups Earnings View</title>
		<link>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064</link>
		<comments>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064#comments</comments>
		<pubDate>Thu, 17 Dec 2009 05:22:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23064</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) increased its earnings expectations for the first quarter of fiscal 2010 and stated that it expects earnings to exceed consensus estimates of 43 cents, mainly due to higher sales of generic drugs. Revenues are expected to grow more than 10% during the quarter. The stock reacted positively to the news, with the share price increasing more than 3%. For fiscal 2010, AmerisourceBergen stated that it expects earnings at the higher end of its previously issued guidance of $1.82 &#8211; $1.92 per share, which represents an increase of 8%-14% over the $1.69 reported by the company in fiscal 2009. The company expects revenue growth in the range of 5% – 7%. Operating margin growth of flat to low single-digit basis points is expected. The company has guided towards ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Eclipses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824</link>
		<comments>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:29:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19824</guid>
		<description><![CDATA[Cardinal Health (CAH) reported fiscal first-quarter earnings per share of 54 cents, surpassing the Zacks Consensus Estimate of 43 cents and the year-ago earnings of 47 cents. Sales Total sales in the reported quarter increased 6% year over year to $24.8 billion. Growth was witnessed across all the business segments. Pharmaceutical segment revenues increased 5% year over year to $22.6 billion. Growth was primarily due to higher sales to existing pharmaceutical distribution customers. Sales to bulk customers increased 6% year over year to $11.3 billion. Sales to non-bulk customers increased 5% year over year to $11.2 billion. Medical segment revenues increased 10% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. In addition, the CareFusion Corp. (CFN) spin-off has resulted in immediate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Tops Consensus Forecasts</title>
		<link>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596</link>
		<comments>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596#comments</comments>
		<pubDate>Wed, 04 Nov 2009 23:55:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19596</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted fourth quarter earnings of 44 cents per share, beating the Zacks Consensus Estimate by 4 cents. Earnings increased 22% from the year-ago period. For the full year, earnings increased 17% to $1.69 per share, 3 cents above the Zacks Consensus Estimate. Performance was driven by strong revenues, lower operating expenses and share repurchases. Total revenues for the quarter increased 9% to $18.7 billion. This was attributable to a 10% growth in AmerisourceBergen Drug Corp. revenues, which was driven primarily by new business and improved market growth and an 8% rise in specialty group sales. Generic revenues remained strong during the quarter, displaying above-market growth. For fiscal 2009, total revenues increased 2% to $71.8 billion. Gross profit for the fourth quarter was $538.5 million, which reflected a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Beats Estimates &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071</link>
		<comments>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:43:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19071</guid>
		<description><![CDATA[McKesson Corp. (MCK) reported its fiscal second-quarter earnings of $1.07 per share, beating the Zacks Consensus Estimate of $1.01. However, earnings declined from the year-ago profit of $1.17. Meanwhile, revenues increased 1.9% to $27.1 billion. The Distribution Solutions segment grew 2% with the U.S. pharmaceutical distribution business recording a 2% increase in revenues. The loss of two customer buying groups in the U.S. continued to impact the performance of this segment. We believe the performance of the Distribution Solutions segment will continue to be impacted by the lost business through the remainder of the year. Canadian revenues grew 9% as the Canadian pharmaceutical market remained slightly stronger than the U.S. market. Medical-Surgical distribution revenues also increased (up 5%), benefiting from small acquisitions made by the company in late fiscal 2009. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/mck-mckesson-beats-estimates-raises-guidance/19071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Completes Spin-Off &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268</link>
		<comments>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:49:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14268</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) has completed the spin-off of its Clinical and Medical Products business to form a subsidiary, CareFusion Corporation (CFN). The spin-off was completed through a pro rata distribution of roughly 81% of CareFusion’s common stock. Roughly 222 million shares of CareFusion common stock were outstanding on the date of distribution. Of this, 180 million shares (81%) were distributed to Cardinal Health shareholders on a pro rata basis. Cardinal Health retained the balance 41 million shares, which will be divested within the next five years. Cardinal Health shareholders received 0.5 share of CareFusion common stock for each share of Cardinal Health they hold. We think that the spin-off will help Cardinal Health unlock the value of the assets tied to CareFusion and concentrate more on its core Healthcare ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Makes Buyback Offer</title>
		<link>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829</link>
		<comments>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829#comments</comments>
		<pubDate>Sat, 29 Aug 2009 00:08:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13829</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) has offered to buy back $1.2 billion of its long-term debt securities (notes) as part of its plan to reduce long-term debt after spinning off its CareFusion Corporation division on Aug 31, 2009. These securities carry maturity dates from 2011 to 2026. The offer expires on Sept. 24 and the owners of these securities must tender their notes by Sept 10 to receive the early tender premium. The notes were issued by Cardinal Health and its subsidiary, Allegiance Corp., Cardinal will finance the buyback with a combination of both cash in hand and a $1.4 billion it is expecting to generate from the CareFusion spin-off. The amount remaining after financing the tender offer will be used for retiring notes due in Oct 2009. We view the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sees Positive Results for Skin Preparation Drug</title>
		<link>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621</link>
		<comments>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621#comments</comments>
		<pubDate>Thu, 27 Aug 2009 18:57:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13621</guid>
		<description><![CDATA[Cardinal Health Inc. (CAH) announced that the use of the preoperative skin preparation, ChloraPrep, is significantly more effective than both DuraPrep and povidone-iodine at eliminating overall bacteria from the shoulder region. After antisepsis with ChloraPrep, only 7% of skin cultures tested positive for bacteria compared to 19% for DuraPrep and 31% for povidone-iodine. The data was published by The Journal of Bone and Joint Surgery recently. ChloraPrep is a product of Cardinal Health’s subsidiary, CareFusion, which the company will spin-off with effect from Aug 31. ChloraPrep is a preoperative skin preparation that reduces bacteria and other microorganisms on the patients&#8217; skin before any medical and surgical procedures. The drug remains effective for at least 48 hours after its application and reduces the risk of dangerous bloodstream and surgical site infections. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal&#8217;s Spin-off to be Added to S&amp;P 500 Index</title>
		<link>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360</link>
		<comments>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360#comments</comments>
		<pubDate>Tue, 25 Aug 2009 20:22:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Manitowoc Company Inc.]]></category>
		<category><![CDATA[MTW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13360</guid>
		<description><![CDATA[Cardinal Health Inc. (CAH) announced that its spin-off subsidiary, CareFusion Corp., will be included in the S&#38;P 500 after the close of trading on Aug 31. CareFusion replaces The Manitowoc Co. Inc. (MTW) in the index and will be added to the S&#38;P 500 GICS (Global Industry Classification Standard) Health Care Equipment Sub-Industry index. CareFusion is being formed by spinning off the Clinical and Medical Products business of Cardinal Health. The spin-off is expected to be completed on Aug 31. CareFusion Corp. is expected to generate earnings per share of $1.10 to $1.20 on a standalone basis. The S&#38;P 500 represents prices of the top 500 large-cap companies traded in the U.S. stock exchanges. It is one of the world’s most prestigious indices. Hundreds of billions of US dollars are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Ltd &#8211; ROE of 83% sits high above the industry average of 15%</title>
		<link>http://www.stockbloghub.com/2009/07/31/hlf-herbalife-ltd-roe-of-83-sits-high-above-the-industry-average-of-15/11737</link>
		<comments>http://www.stockbloghub.com/2009/07/31/hlf-herbalife-ltd-roe-of-83-sits-high-above-the-industry-average-of-15/11737#comments</comments>
		<pubDate>Fri, 31 Jul 2009 22:33:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Herbalife Ltd.]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=11737</guid>
		<description><![CDATA[Herbalife Ltd. (HLF) is seeing bullish Zacks Consensus Estimates ahead of reporting next week. The full-year forecast of $2.97 per share is up 3% over the past 3 months. The most accurate 2009 Zacks Consensus Estimate is even higher at $3.12. Company Description Herbalife sells weight-management, nutrition, and personal care products. The company&#8217;s products are sold in 70 countries through a network of over 1.9 million independent distributors. Zacks Consensus Estimates are on the Rise The company is scheduled to release second-quarter results on August 3. During the past 3 months, shares of HLF have soared past the market by more than 50%. Ahead of reporting, Zacks Consensus Estimates for earnings have been climbing across the board. Second-quarter projections of 72 cents per share are above the 3 months-ago level ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/31/hlf-herbalife-ltd-roe-of-83-sits-high-above-the-industry-average-of-15/11737/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HLF) Herbalife Ltd. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/07/14/hlf-herbalife-ltd-momentum-zacks-rank-buy/9931</link>
		<comments>http://www.stockbloghub.com/2009/07/14/hlf-herbalife-ltd-momentum-zacks-rank-buy/9931#comments</comments>
		<pubDate>Tue, 14 Jul 2009 14:26:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Herbalife Ltd.]]></category>
		<category><![CDATA[HLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=9931</guid>
		<description><![CDATA[Herbalife Ltd. (HLF) recently announced it had received licenses to sell its products in a number of Chinese provinces, creating a sales channel directed towards millions of potential customers. Company Description Herbalife Ltd sells weight management and nutritional supplement products worldwide. The company sells its products through a network of independent distributors and has a market cap of $1.83 billion. Shares of HLF have been resilient in the face of a tough economy, helped by the company&#8217;s first-quarter earnings beat, reported on May 4. First-Quarter Results Sales were down 14% from last year to $521.7 million, but earnings came in at 68 cents per share, 9 cents ahead of the consensus. The company has surprised and beat in each of the last four quarters by an average of 6 cents, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/14/hlf-herbalife-ltd-momentum-zacks-rank-buy/9931/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NUS) Nu Skin Enterprises  &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/06/19/nus-nu-skin-enterprises-growth-and-income-zacks-rank-buy/8627</link>
		<comments>http://www.stockbloghub.com/2009/06/19/nus-nu-skin-enterprises-growth-and-income-zacks-rank-buy/8627#comments</comments>
		<pubDate>Fri, 19 Jun 2009 21:00:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Nu Skin Enterprises Inc.]]></category>
		<category><![CDATA[NUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8627</guid>
		<description><![CDATA[Nu Skin Enterprises (NUS) recently declared a quarterly dividend of $0.115 per share, noting that it is payable on June 25 to shareholders of record on June 15. The company is yielding an industry-leading 3%. Company Description Nu Skin Enterprises is a $1 billion direct selling company that markets and distributes premium quality personal care, nutrition and technology products through a global network of more than 750,000 active independent distributors and preferred customers. The company operates three core brands, Nu Skin, Pharmanex, and Big Planet. The Nu Skin brand has a line of more than 100 premium skin treatment and other personal care products. With a team of more than 100 in-house scientists, Pharmanex uses a pharmaceutical approach that is setting the standard for the dietary supplement industry. Big Planet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/19/nus-nu-skin-enterprises-growth-and-income-zacks-rank-buy/8627/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NUS) Nu Skin Enterprises, Inc. &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/05/20/nus-nu-skin-enterprises-inc-growth-and-income-zacks-rank-buy/7224</link>
		<comments>http://www.stockbloghub.com/2009/05/20/nus-nu-skin-enterprises-inc-growth-and-income-zacks-rank-buy/7224#comments</comments>
		<pubDate>Wed, 20 May 2009 19:40:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Nu Skin Enterprises Inc.]]></category>
		<category><![CDATA[NUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7224</guid>
		<description><![CDATA[Nu Skin Enterprises, Inc. (NUS) recently posted first-quarter earnings of 28 cents per share, excluding an item. The result exceeded analysts&#8217; estimates by 17%. Management said the company continues to produce growth in a difficult economic climate. Company Description Nu Skin Enterprises is a $1 billion direct selling company that markets and distributes premium quality personal care, nutrition and technology products through a global network of more than 750,000 active independent distributors and preferred customers. The company operates three core brands, Nu Skin, Pharmanex, and Big Planet. The Nu Skin brand has a line of more than 100 premium skin treatment and other personal care products. With a team of more than 100 in-house scientists, Pharmanex uses a pharmaceutical approach that is setting the standard for the dietary supplement industry. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/20/nus-nu-skin-enterprises-inc-growth-and-income-zacks-rank-buy/7224/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NUS) Nu Skin Enterprises, Inc. &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/05/07/nus-nu-skin-enterprises-inc-value-zacks-rank-buy/6676</link>
		<comments>http://www.stockbloghub.com/2009/05/07/nus-nu-skin-enterprises-inc-value-zacks-rank-buy/6676#comments</comments>
		<pubDate>Thu, 07 May 2009 23:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Nu Skin Enterprises Inc.]]></category>
		<category><![CDATA[NUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=6676</guid>
		<description><![CDATA[Nu Skin Enterprises, Inc. (NUS) is playing the youth revolution as sales of its anti-aging and spa skin products jumped in the first quarter. The company has surprised on estimates 2 out of the last 4 quarters. NUS has attractive value characteristics, trading at 10.5x forward earnings. Company Description Nu Skin Enterprises is a direct selling business with three brands including Nu Skin personal skin care line, Pharmanex and Big Planet. The company operates in 48 markets around the globe and has 750,000 independent sales representatives. The Nu Skin segment specializes in anti-aging products including the Galvanic Spa System II. Pharmanex manufactures weight loss products, nutritional supplements as well as the nutrition beverage g3. The Big Planet segment offers the Photomax product line which allows customers to store and organize ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/07/nus-nu-skin-enterprises-inc-value-zacks-rank-buy/6676/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health, Inc.:  Stock of the Day</title>
		<link>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691</link>
		<comments>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691#comments</comments>
		<pubDate>Tue, 17 Feb 2009 22:36:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[W.W. Grainger]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2691</guid>
		<description><![CDATA[by David Fessler, Advisory Panelist, Investment U When we think of industrial suppliers, W.W. Grainger (NYSE:GWW) is one of the largest in the business. From nuts and bolts to janitorial supplies, it’s a good bet Grainger’s can supply it. The company consolidates parts, equipment and supplies from thousands of manufacturers and provides customers with one-stop shopping, both on its website and from its huge four inch thick catalog. Grainger’s has been bucking the trend and doing reasonably well during this business contraction. However it did acknowledge that business conditions in 2009 will be challenging, and its first quarter sales will be significantly lower than last quarter. As dismal as that sounds Grainger should be one of the first to benefit from the upswing when it comes. Motors, fans, bearings and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

